Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Predicting inductive drug-drug interactions.

Christopher Liddle1, Graham R Robertson

  • 1Department of Clinical Pharmacology, Storr Liver Unit, Westmead Millennium Institute and University of Sydney, Westmead Hospital, Westmead, NSW 2145, Australia. chris_liddle@wmi.usyd.edu.au

Pharmacogenomics
|February 28, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

HDAC INHIBITION SENSITIZES PANCREATIC TUMORS TO DNA DAMAGE BY GLOBAL REDISTRIBUTION OF THE TRANSCRIPTIONAL MACHINERY.

bioRxiv : the preprint server for biology·2026
Same author

Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.

Nature cancer·2026
Same author

Pancreatic volume and immune biomarkers predict checkpoint inhibitor-associated autoimmune diabetes in humans.

The Journal of clinical investigation·2025
Same author

Estrogen-related receptors regulate innate and adaptive muscle mitochondrial energetics through cooperative and distinct actions.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

BCL6 coordinates muscle mass homeostasis with nutritional states.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same journal

Closely similar tacrolimus morning troughs and graft function across the recipients' common <i>ABCB1</i> polymorphisms (<i>c.2677G>T/A</i>, <i>c.1236C>T</i>, <i>c.3435C>T</i>) early after renal transplantation.

Pharmacogenomics·2026
Same journal

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics·2026
Same journal

Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".

Pharmacogenomics·2026
Same journal

Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models.

Pharmacogenomics·2026
Same journal

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Pharmacogenomics·2026
Same journal

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care.

Pharmacogenomics·2026
See all related articles

Predicting drug-drug interactions is now easier. New assays identify potential drug metabolism gene induction before human trials, improving drug safety and preventing post-marketing issues.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Drug Development

Background:

  • Predicting inductive drug-drug interactions (DDIs) pre-clinically has been challenging.
  • Many significant DDIs are discovered late, often post-marketing, after clinical events.
  • Nuclear receptors act as xenobiotic sensors, regulating genes for drug metabolism and excretion.

Purpose of the Study:

  • To leverage recent advances in nuclear receptor biology for improved DDI prediction.
  • To develop novel assay systems for early detection of drug-induced gene induction.
  • To facilitate proactive identification of potential DDIs before human pharmacokinetic studies.

Main Methods:

  • Investigating molecular and cellular biology of nuclear receptors as xenobiotic sensors.

Related Experiment Videos

  • Developing and validating in vitro assay systems to measure gene induction potential.
  • Utilizing knowledge of nuclear receptor mechanisms to design predictive assays.

    • Main Results:

    • Identification of nuclear receptors as key regulators of drug metabolism and excretion genes.
    • Development of functional assay systems capable of detecting xenobiotic-induced gene transactivation.
    • Demonstration that these assays can predict the potential for DDIs early in drug development.

    Conclusions:

    • Advances in understanding nuclear receptor signaling enable early prediction of DDIs.
    • New assay systems allow for the detection of gene induction potential before clinical trials.
    • This approach promises to enhance drug safety and reduce post-marketing surprises.